Pain
May 6, 2008
QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
“Initial Phase 3 efficacy data demonstrated statistically significant analgesic activity at all doses tested and reinforces the potential clinical benefit and commercial value of QRxPharma's lead dual-opioid product”
"Initial Phase 3 efficacy data demonstrated statistically significant analgesic activity at all doses tested and reinforces the potential clinical benefit and commercial value of QRxPharma's lead dual-opioid ... via Rehab Management
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Addicted to Pain-Killers? (from Apr '07) | 2 hr | miss | 704 |
| FDA Warns About Cipro, Other Antibiotics | 3 hr | Ty Taylor | 31 |
| House passes bill to temporarily ban new methad... (from Mar '07) | 4 hr | Ruby_Tuesday | 24 |
| What is Ultram? (from Nov '06) | 7 hr | shelly | 233 |
| Opioid Addiction: No Reason to Withhold Pain Ma... | Tue | Ban Methadone | 32 |
| Genital herpes common, but percentage is declining | Tue | this articl... | 11 |
| FDA calls for urgent warning on tendon risks | Jul 21 | mimi | 11 |
Most Popular
